I-Mab ADR (IMAB) saw an uptrend of 2585330% in the recent trading with $490190.0 being its most recent. The current price level -16.42% lower than the highest price of $3.08 marked by the stock while trading over the past 52-weeks, whereas it is 331.93% higher than the lowest price of $0.60 the company dropped to over past 52-weeks. The latest news story on IMAB appeared in (GlobeNewswire) under the title “I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025” on Jun-26-25.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
I-Mab ADR Earnings – What Happened With IMAB
Coming around sales and income figures on IMAB Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
I-Mab ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 78.94 million. IMAB does have institutional investors; and they hold 11.85% of the stock.
As on 2024-06-30, HHLR ADVISORS, LTD. was the top most holder in I-Mab ADR (NASDAQ:IMAB) with an ownership of 6.91 million shares of the company or 7.7935 of the stake worth $11.54 million. The filing also reveals CALIGAN PARTNERS LP as the second largest holder in the company with a control over 3.8067 of the outstanding shares. Its stake is worth $5.64 million for having 3.37 million shares in hand.
BOOTHBAY FUND MANAGEMENT, LLC also came holding a key position in the company during the recent quarter and it now holds 1.5559 of the outstanding shares. With this there are now 34.0 institutions which have possession in IMAB’s shares.
Key Metrics forIMAB
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, I-Mab ADR has a debt to equity ratio of 0.02.
Technical Analysis of I-Mab ADR (NASDAQ:IMAB) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for I-Mab ADR (IMAB), we notice that the stock’s 20-day average volume is at 1,184,565 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 576,194 shares. And to end, IMAB’s 100-day average volume is 417,276 shares with 100% of the long-term indicators pointing towards Buy for the stock.
